A Safety and Efficacy Study of Ramelteon Tablets for Sublingual Administration (TAK-375SL) in the Maintenance Treatment of Bipolar 1 Disorder
NCT ID: NCT01685151
Last Updated: 2013-01-23
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
WITHDRAWN
Clinical Phase
PHASE3
Study Classification
INTERVENTIONAL
Study Start Date
2012-09-30
Study Completion Date
2015-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
To evaluate the efficacy and safety of once a day ramelteon tablets for sublingual administration (TAK-375SL) in the maintenance treatment of bipolar 1 disorder.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
NCT01677182
Bipolar Disorder
TERMINATED
PHASE3
Efficacy and Safety of Ramelteon Sublingual as Adjunctive Therapy for Maintenance Treatment of Bipolar I Disorder
NCT01467713
Bipolar Disorder
TERMINATED
PHASE3
Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder
NCT01467700
Acute Depressive Episode
TERMINATED
PHASE3
Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder
NCT04285515
Bipolar Depression
Major Depressive Disorder
COMPLETED
PHASE3
Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally
NCT03249376
Bipolar Depression
COMPLETED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The drug being tested in this study is called Ramelteon. Ramelteon is being tested to treat people who have Bipolar 1 Disorder. This study will look at the symptoms of bipolar disorder in people who take Ramelteon.
The study will enroll approximately 495 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the three treatment groups-which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need):
* Ramelteon (Dose 1)
* Ramelteon (Dose 2)
* Placebo (dummy inactive pill) - this is a tablet that looks like the study drug but has no active ingredient All participants will be asked to take one tablet every night at bedtime throughout the study.
This multi-centre trial will be conducted in North America and Europe. The overall time to participate in this study is 13 months. Participants will make 17 visits to the clinic, and will be contacted by telephone 30 days after last dose of study drug for a follow-up assessment.
This 12-month study was designed to evaluate the efficacy of TAK-375SL in the maintenance treatment of bipolar 1 disorder. At this time, Takeda has decided to withdraw the study for business reasons. No participants were enrolled in this study.
The study will enroll approximately 495 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the three treatment groups-which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need):
* Ramelteon (Dose 1)
* Ramelteon (Dose 2)
* Placebo (dummy inactive pill) - this is a tablet that looks like the study drug but has no active ingredient All participants will be asked to take one tablet every night at bedtime throughout the study.
This multi-centre trial will be conducted in North America and Europe. The overall time to participate in this study is 13 months. Participants will make 17 visits to the clinic, and will be contacted by telephone 30 days after last dose of study drug for a follow-up assessment.
This 12-month study was designed to evaluate the efficacy of TAK-375SL in the maintenance treatment of bipolar 1 disorder. At this time, Takeda has decided to withdraw the study for business reasons. No participants were enrolled in this study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Bipolar Disorder
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ramelteon SL (Dose 1)
Ramelteon SL tablets, sublingual, once daily, at night time for up to 12 months.
Group Type
EXPERIMENTAL
Ramelteon SL (Dose 1)
Intervention Type
DRUG
Ramelteon tablets for sublingual administration
Ramelteon SL (Dose 2)
Ramelteon SL tablets, sublingual, once daily, at nigh time for up to 12 months
Group Type
EXPERIMENTAL
Ramelteon SL (Dose 2)
Intervention Type
DRUG
Ramelteon tablets for sublingual administration
Placebo
Ramelteon SL placebo-matching tablets, sublingual, once daily, at night time for up to 12 months.
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
DRUG
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ramelteon SL (Dose 1)
Ramelteon tablets for sublingual administration
Intervention Type
DRUG
Ramelteon SL (Dose 2)
Ramelteon tablets for sublingual administration
Intervention Type
DRUG
Placebo
Placebo
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
TAK-375SL
Rozerem
TAK-375SL
Rozerem
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. In the opinion of the investigator, the subject is capable of understanding and complying with protocol requirements.
2. The subject or a legally acceptable representative signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
3. The subject suffers from bipolar 1 disorder, according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria and is confirmed by the Structured Clinical Interview for DSM Disorders (SCID).
4. The subject is a man or woman aged between 18 and 75 years, inclusive.
5. The subject has an identified caregiver or person responsible (eg. Family member, spouse, case worker or nurse at a residential living facility) that is considered reliable by the investigator.
6. The most recent mood episode (depression, mania, mixed episode, hypomania) is between 8 weeks and 9 months prior to screening.
7. The subject has been stable in the opinion of the PI for at least 8 weeks prior to baseline from their most recent mood episode.
8. The subject has a MADRS total score ≤12 at the Screening and Baseline visits.
9. The subject has a YMRS score of ≤10 both at the Screening and Baseline visits.
10. The subject has a CGI-S score of ≤2 at the Screening and Baseline visits.
11. HAM-A score is ≤21 at Screening and Baseline visits.
12. The subject's medications for bipolar 1 disorder are stable ie, no change in psychotropic medications and no dose adjustment of psychotropic medications for bipolar 1 disorder has been made for at least 8 weeks prior to the randomization.
13. A male subject who is nonsterilized and sexually active with a female partner of childbearing potential agrees to use adequate contraception from signing of informed consent throughout the duration of the study and for 30 days after the last dose.
14. A female subject of childbearing potential who is sexually active with a nonsterilized male partner agrees to use routinely adequate contraception from signing of informed consent throughout the duration of the study and for 30 days after the last dose.
2. The subject or a legally acceptable representative signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
3. The subject suffers from bipolar 1 disorder, according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria and is confirmed by the Structured Clinical Interview for DSM Disorders (SCID).
4. The subject is a man or woman aged between 18 and 75 years, inclusive.
5. The subject has an identified caregiver or person responsible (eg. Family member, spouse, case worker or nurse at a residential living facility) that is considered reliable by the investigator.
6. The most recent mood episode (depression, mania, mixed episode, hypomania) is between 8 weeks and 9 months prior to screening.
7. The subject has been stable in the opinion of the PI for at least 8 weeks prior to baseline from their most recent mood episode.
8. The subject has a MADRS total score ≤12 at the Screening and Baseline visits.
9. The subject has a YMRS score of ≤10 both at the Screening and Baseline visits.
10. The subject has a CGI-S score of ≤2 at the Screening and Baseline visits.
11. HAM-A score is ≤21 at Screening and Baseline visits.
12. The subject's medications for bipolar 1 disorder are stable ie, no change in psychotropic medications and no dose adjustment of psychotropic medications for bipolar 1 disorder has been made for at least 8 weeks prior to the randomization.
13. A male subject who is nonsterilized and sexually active with a female partner of childbearing potential agrees to use adequate contraception from signing of informed consent throughout the duration of the study and for 30 days after the last dose.
14. A female subject of childbearing potential who is sexually active with a nonsterilized male partner agrees to use routinely adequate contraception from signing of informed consent throughout the duration of the study and for 30 days after the last dose.
Exclusion Criteria
1. The subject has received any investigational compound \<30 days before Screening or 5 half-lives prior to Screening, whichever is longer.
2. The subject has ever received TAK-375 or TAK-375 SL in a previous clinical study or has ever used ramelteon.
3. The subject is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress.
4. The subject has one or more of the following:
1. Any current psychiatric disorder which is the primary focus of treatment other than bipolar 1 disorder as defined in the DSM-IV-TR, as assessed by the SCID.
2. Current or history of: schizophrenia or any other psychotic disorder, including schizoaffective disorder, major depression with psychotic features, bipolar depression with psychotic features (with the exception of psychosis associated with a manic or mixed episode), OCD, mental retardation, organic mental disorders, or mental disorders due to a general medical condition as defined in the DSM-IV-TR.
3. Current diagnosis or history of alcohol or other substance abuse (excluding nicotine or caffeine) as defined in the DSM-IV-TR that has not been in full and sustained remission for at least three months from the day of screening (Subject must also have negative urine drug screen at Screening and Baseline; only exception is for benzodiazepines and opiates provided the subject has a valid prescription).
4. Current diagnosis or history of alcohol or other substance dependence (excluding nicotine or caffeine) as defined in the DSM-IV-TR that has not been in full and sustained remission for at least three months from the day of screening.(Subject must also have negative urine drug screen at Screening and Baseline; only exception is for benzodiazepines and opiates provided the subject has a valid prescription).
5. Presence or history of a clinically significant neurological disorder (including epilepsy) as determined by the investigator.
6. Neurodegenerative disorder (Alzheimer disease, Parkinson disease, multiple sclerosis, Huntington disease, etc).
7. Any Axis II disorder that might compromise the study.
8. History of Rapid Cycling Bipolar Disorder: Subjects who have more than 8 episodes of mood disorder per year. The episodes must meet both the duration and symptom criteria for a Major Depressive, Manic, Mixed, or Hypomanic episode and must be demarcated by either a period of full remission or by a switch to an episode of the opposite polarity. Manic, Hypomanic, and Mixed Episodes are counted as being on the same pole. Each mood episode must be confirmed by appropriate patient history or formal diagnosis by medical practitioner.
5. The subject experienced the first episode of mood disorder after the age of 55 years.
6. The subject is on any other medications other than antidepressants (except fluvoxamine), mood stabilizers (lithium, valproate, lamotrigine), or atypical antipsychotics (risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole,) for bipolar 1 disorder. If the subject is on lithium and/or valproate, the levels should be in the specified range: lithium (serum levels up to 1.2 mEq/L); valproate (serum levels up to 125 mcg/ml) at screening. If the subject is on any other psychotropic medications, at the investigators discretion, withdrawal of these medications is allowed two weeks prior to the baseline visit.
7. The subject is on no medications or taking only antidepressant medications (or taking only other medications not commonly used as standard treatment for bipolar I disorder, such as benzodiazepines).
8. The subject has received electroconvulsive therapy, vagal nerve stimulation, or repetitive transcranial magnetic stimulation within 6 months prior to Screening.
9. The subject has started receiving formal cognitive or behavioral therapy, systematic psychotherapy within 30 days from screening or plans to initiate such therapy during the study (supportive therapy, marital therapy and bereavement counseling are allowed).
10. The subject has a significant risk of suicide according to the investigator's clinical judgment or has a score ≥5 on item 10 (suicidal thoughts) of the MADRS or has made a suicide attempt in the previous 6 months.
11. The subject is required to take excluded medications or it is anticipated that the subject will require treatment with at least 1 of the disallowed concomitant medications during the study.
12. The subject has a clinically significant unstable illness, for example hepatic impairment or renal insufficiency, or a cardiovascular, pulmonary, gastrointestinal, endocrine, neurological, rheumatologic, immunologic, hematological, infectious, dermatological disorder or metabolic disturbance.
13. The subject has a history or current diagnosis of Fibromyalgia, Chronic Fatigue Syndrome, Chronic Pain Syndrome or Sleep apnea (central and/or obstructive). If obstructive sleep apnea is corrected surgically, a polysomnogram showing normal apnea-hypopnea index is required.
14. The subject has a previous history of cancer that had been in remission for less than 5 years prior to the first dose of study medication. This criterion does not include those subjects with basal cell or stage I squamous cell carcinoma of the skin.
15. The subject has 1 or more laboratory value outside the normal range, based on the blood or urine samples taken at the Screening Visit, that are considered by the investigator to be clinically significant; or the subject has any of the following values at the Screening Visit:
1. A serum creatinine value \>1.5 times the upper limits of normal (xULN).
2. A serum total bilirubin value \>1.5 xULN.
3. A serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value \>2 xULN.
16. The subject has glycosylated hemoglobin (HbA1C) ≥7% at screening and no prior diagnosis of diabetes and/or treatment for diabetes. NOTE: Subjects with known diabetes are not excluded.
17. The subject has a thyroid stimulating hormone (TSH) value outside the normal range at the Screening Visit that is deemed clinically significant by the investigator. NOTE: Free T4 will be checked if TSH is out of range. If free T4 is abnormal the subject will be excluded.
18. Positive for Hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV) antibodies, or a history of Human immunodeficiency virus (HIV) infection
19. If male, the subject intends to donate sperm during the course of this study or for 12 weeks thereafter. If female, the subject is pregnant or lactating or intending to become pregnant before, during, or within 30 days after participating in this study; or intending to donate ova during such time period.
20. The subject has clinically significant abnormal vital signs as determined by the investigator.
21. The subject has an abnormal electrocardiogram (ECG)as determined by the central reader and confirmed as clinically significant by the investigator.
22. The subject has a disease or takes medication that, in the opinion of the investigator, could interfere with the assessments of safety, tolerability, or efficacy.
23. The subject has a positive urine drug screen. NOTE: Positive urine drug screens for benzodiazepines and opiates for which the subject has a valid prescription will be allowed.
24. The subject, in the opinion of the investigator, is unlikely to comply with the clinical study protocol or is unsuitable for any reason.
2. The subject has ever received TAK-375 or TAK-375 SL in a previous clinical study or has ever used ramelteon.
3. The subject is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress.
4. The subject has one or more of the following:
1. Any current psychiatric disorder which is the primary focus of treatment other than bipolar 1 disorder as defined in the DSM-IV-TR, as assessed by the SCID.
2. Current or history of: schizophrenia or any other psychotic disorder, including schizoaffective disorder, major depression with psychotic features, bipolar depression with psychotic features (with the exception of psychosis associated with a manic or mixed episode), OCD, mental retardation, organic mental disorders, or mental disorders due to a general medical condition as defined in the DSM-IV-TR.
3. Current diagnosis or history of alcohol or other substance abuse (excluding nicotine or caffeine) as defined in the DSM-IV-TR that has not been in full and sustained remission for at least three months from the day of screening (Subject must also have negative urine drug screen at Screening and Baseline; only exception is for benzodiazepines and opiates provided the subject has a valid prescription).
4. Current diagnosis or history of alcohol or other substance dependence (excluding nicotine or caffeine) as defined in the DSM-IV-TR that has not been in full and sustained remission for at least three months from the day of screening.(Subject must also have negative urine drug screen at Screening and Baseline; only exception is for benzodiazepines and opiates provided the subject has a valid prescription).
5. Presence or history of a clinically significant neurological disorder (including epilepsy) as determined by the investigator.
6. Neurodegenerative disorder (Alzheimer disease, Parkinson disease, multiple sclerosis, Huntington disease, etc).
7. Any Axis II disorder that might compromise the study.
8. History of Rapid Cycling Bipolar Disorder: Subjects who have more than 8 episodes of mood disorder per year. The episodes must meet both the duration and symptom criteria for a Major Depressive, Manic, Mixed, or Hypomanic episode and must be demarcated by either a period of full remission or by a switch to an episode of the opposite polarity. Manic, Hypomanic, and Mixed Episodes are counted as being on the same pole. Each mood episode must be confirmed by appropriate patient history or formal diagnosis by medical practitioner.
5. The subject experienced the first episode of mood disorder after the age of 55 years.
6. The subject is on any other medications other than antidepressants (except fluvoxamine), mood stabilizers (lithium, valproate, lamotrigine), or atypical antipsychotics (risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole,) for bipolar 1 disorder. If the subject is on lithium and/or valproate, the levels should be in the specified range: lithium (serum levels up to 1.2 mEq/L); valproate (serum levels up to 125 mcg/ml) at screening. If the subject is on any other psychotropic medications, at the investigators discretion, withdrawal of these medications is allowed two weeks prior to the baseline visit.
7. The subject is on no medications or taking only antidepressant medications (or taking only other medications not commonly used as standard treatment for bipolar I disorder, such as benzodiazepines).
8. The subject has received electroconvulsive therapy, vagal nerve stimulation, or repetitive transcranial magnetic stimulation within 6 months prior to Screening.
9. The subject has started receiving formal cognitive or behavioral therapy, systematic psychotherapy within 30 days from screening or plans to initiate such therapy during the study (supportive therapy, marital therapy and bereavement counseling are allowed).
10. The subject has a significant risk of suicide according to the investigator's clinical judgment or has a score ≥5 on item 10 (suicidal thoughts) of the MADRS or has made a suicide attempt in the previous 6 months.
11. The subject is required to take excluded medications or it is anticipated that the subject will require treatment with at least 1 of the disallowed concomitant medications during the study.
12. The subject has a clinically significant unstable illness, for example hepatic impairment or renal insufficiency, or a cardiovascular, pulmonary, gastrointestinal, endocrine, neurological, rheumatologic, immunologic, hematological, infectious, dermatological disorder or metabolic disturbance.
13. The subject has a history or current diagnosis of Fibromyalgia, Chronic Fatigue Syndrome, Chronic Pain Syndrome or Sleep apnea (central and/or obstructive). If obstructive sleep apnea is corrected surgically, a polysomnogram showing normal apnea-hypopnea index is required.
14. The subject has a previous history of cancer that had been in remission for less than 5 years prior to the first dose of study medication. This criterion does not include those subjects with basal cell or stage I squamous cell carcinoma of the skin.
15. The subject has 1 or more laboratory value outside the normal range, based on the blood or urine samples taken at the Screening Visit, that are considered by the investigator to be clinically significant; or the subject has any of the following values at the Screening Visit:
1. A serum creatinine value \>1.5 times the upper limits of normal (xULN).
2. A serum total bilirubin value \>1.5 xULN.
3. A serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value \>2 xULN.
16. The subject has glycosylated hemoglobin (HbA1C) ≥7% at screening and no prior diagnosis of diabetes and/or treatment for diabetes. NOTE: Subjects with known diabetes are not excluded.
17. The subject has a thyroid stimulating hormone (TSH) value outside the normal range at the Screening Visit that is deemed clinically significant by the investigator. NOTE: Free T4 will be checked if TSH is out of range. If free T4 is abnormal the subject will be excluded.
18. Positive for Hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV) antibodies, or a history of Human immunodeficiency virus (HIV) infection
19. If male, the subject intends to donate sperm during the course of this study or for 12 weeks thereafter. If female, the subject is pregnant or lactating or intending to become pregnant before, during, or within 30 days after participating in this study; or intending to donate ova during such time period.
20. The subject has clinically significant abnormal vital signs as determined by the investigator.
21. The subject has an abnormal electrocardiogram (ECG)as determined by the central reader and confirmed as clinically significant by the investigator.
22. The subject has a disease or takes medication that, in the opinion of the investigator, could interfere with the assessments of safety, tolerability, or efficacy.
23. The subject has a positive urine drug screen. NOTE: Positive urine drug screens for benzodiazepines and opiates for which the subject has a valid prescription will be allowed.
24. The subject, in the opinion of the investigator, is unlikely to comply with the clinical study protocol or is unsuitable for any reason.
Minimum Eligible Age
18 Years
Maximum Eligible Age
75 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Takeda
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director Clinical Science
Role: STUDY_DIRECTOR
Takeda Global Research and Development Center, Inc.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2012-001373-85
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
U1111-1129-5093
Identifier Type: REGISTRY
Identifier Source: secondary_id
TAK-375SL_302
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Safety and Efficacy of MEM 1003 Versus Placebo for the Treatment of Patients With Bipolar I Disorder
NCT00374920
COMPLETED
PHASE2
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
NCT06372964
RECRUITING
PHASE3
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
NCT01121536
TERMINATED
PHASE3
Lamotrigine Alone Compared to Lamotrigine Plus Antidepressant for the Treatment of Bipolar II Depression
NCT00475137
COMPLETED
PHASE2
Lamotrigine Phase III Study in Bipolar I Disorder
NCT01602510
COMPLETED
PHASE3
Lamictal as Add-on Treatment for Bipolar I Disorder in Pediatric Patients
NCT00723450
COMPLETED
PHASE3
Efficacy of Adjunctive Tianeptine in the Treatment of Bipolar Depression
NCT00879372
UNKNOWN
PHASE3
Accelerated Theta Burst Stimulation for Inpatients With Bipolar Disorder
NCT04058249
TERMINATED
NA
Liothyronine (T3) for Bipolar Depression
NCT00790738
COMPLETED
PHASE3
A Study on the Safety and Efficacy of Topiramate in the Treatment of Patients With Bipolar I Disorder
NCT00037674
COMPLETED
PHASE3
Bipolarity - Depression in Children and Adolescent Suicide Attempters: Better Diagnosis to Prevent Recurrence
NCT03116503
COMPLETED
NA
A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)
NCT07286175
RECRUITING
PHASE2
Depakote Monotherapy, Olanzapine Monotherapy, and Combination Therapy of Depakote Plus Olanzapine in Stable Subjects During the Maintenance Phase of Bipolar Illness
NCT00071253
TERMINATED
PHASE4
Ropinirole in the Treatment of Bipolar Depression
NCT00314821
COMPLETED
PHASE4
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
NCT01072630
COMPLETED
PHASE3
Prophylactic Effect of Lamotrigine Compared With Lithium in Bipolar Disorder
NCT00226135
COMPLETED
PHASE3
A Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
NCT01072929
COMPLETED
PHASE3
Study to Determine the Effectiveness of Risperidone in Bipolar Disorder in Children and Adolescents
NCT00076115
COMPLETED
PHASE3
Levetiracetam in the Management of Bipolar Depression
NCT00566150
COMPLETED
NA
Acute Treatment of Bipolar II Depression
NCT00074776
COMPLETED
PHASE3
Bipolar Study in Adults at Least 18 Years of Age
NCT00067938
COMPLETED
PHASE4
A Trial of SAMe for Treatment-Resistant Bipolar Depression
NCT00762268
COMPLETED
NA
A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes, Associated With Bipolar I Disorder
NCT03257865
COMPLETED
PHASE3
Special Drug Use Investigation for LAMICTAL Bipolar
NCT01428518
COMPLETED